What is the impact of the Guidant acquisition on Abbott's financial performance?

The acquisition of Guidant's vascular intervention and endovascular solutions businesses for approximately $4.1 billion significantly expanded Abbott's Vascular Products segment, leading to substantial sales growth in that area. However, the acquisition also resulted in a large increase in goodwill and intangible assets, significant debt issuance, and related interest expenses, as well as a one-time charge for acquired in-process research and development, which impacted net earnings in the short term.

Why did net earnings decrease in the second quarter of 2006 compared to the prior year?

The decrease in net earnings was primarily driven by a significant $493 million expense recognized for 'Acquired in-process and collaborations research and development' related to the Guidant acquisition. Additionally, net interest expense more than doubled due to increased borrowings to finance the acquisition and related investments, and the loss from the TAP Pharmaceutical Products Inc. joint venture also increased.

What is the company's strategy regarding its investment in Boston Scientific?

Abbott acquired 64.6 million shares of Boston Scientific common stock and loaned $900 million to a subsidiary of Boston Scientific as part of facilitating Boston Scientific's acquisition of Guidant. Abbott is required to dispose of these shares by October 2008, with restrictions on sales until October 2006 and limitations on the monthly volume of sales. The investment represents a significant asset but also carries risks, including potential declines in Boston Scientific's share price and credit risk on the loan.

How is the company managing its debt and liquidity following the Guidant acquisition?

Abbott issued $4.0 billion in long-term debt to help finance the Guidant acquisition. While this increased its debt load and interest expenses, the company maintains strong liquidity with $2.7 billion in cash and cash equivalents at the end of the period and $3.0 billion in unused credit lines. The company expects its operating cash flow to continue exceeding capital expenditures and dividends, indicating confidence in its ability to service its debt and fund operations.

ABT 10-Q Quarterly Report Q2 FY2006 — Revenue, Net Income, EPS

Summary

Abbott Laboratories' (ABT) Q2 2006 filing shows a slight decrease in net sales for the quarter and year-to-date compared to the prior year, primarily impacted by the discontinuation of distribution for certain Boehringer Ingelheim (BI) products and a stronger U.S. dollar. However, excluding the BI products, underlying sales growth remained robust, driven by the significant acquisition of Guidant's vascular intervention and endovascular solutions businesses, which substantially boosted the Vascular Products segment. The company also made substantial investments, including acquiring a significant stake in Boston Scientific, which has led to increased debt and interest expenses. Despite these investments and acquisition-related costs impacting short-term earnings, Abbott's operational performance appears solid, with improvements in gross profit margins due to a more favorable product mix.

Key Highlights

1Net sales for the second quarter of 2006 were $5.501 billion, a slight decrease of 0.4% from $5.524 billion in the prior year. Year-to-date net sales were $10.685 billion, down 2.0% from $10.906 billion.
2Excluding the impact of discontinued Boehringer Ingelheim (BI) products and currency fluctuations, underlying net sales growth was a strong 11.4% for the quarter and 8.3% year-to-date, indicating healthy operational performance.
3The acquisition of Guidant's vascular intervention and endovascular solutions businesses for approximately $4.1 billion significantly boosted the Vascular Products segment, with sales increasing by 323.0% for the quarter and 195.7% year-to-date.
4Net earnings for the quarter declined to $612.2 million ($0.40 per diluted share) from $877.1 million ($0.56 per diluted share) in the prior year, largely due to a substantial increase in 'Acquired in-process and collaborations research and development' expenses ($493 million) and increased net interest expense.
5The company recorded significant cash flow from investing activities, primarily due to the acquisition of Guidant's businesses ($4.321 billion) and investment in Boston Scientific ($2.096 billion), leading to a substantial decrease in cash and cash equivalents.
6Shareholders' equity increased to $15.186 billion from $14.415 billion, supported by earnings employed in the business and other comprehensive income, although offset by significant share repurchases.
7Abbott incurred $4.0 billion in new long-term debt to fund the Guidant acquisition, leading to an increase in net interest expense for the period.

ABBOTT LABORATORIES Quarterly Report for Q2 Ended Jun 30, 2006

Summary

Key Highlights

Frequently Asked Questions